Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19.

ABSTRACT: Cancer significantly contributes to the unfavorable prognosis of coronavirus disease 2019 (COVID-19) patients. The efficacy and safety of azvudine and nirmatrelvir/ritonavir (Paxlovid) in cancer patients with COVID-19 remain uncertain. Therefore, we designed a comprehensive retrospective study encompassing clinical data of 32,864 hospitalized COVID-19 patients, 691 of whom were cancer patients treated with azvudine and 200 were cancer patients treated with Paxlovid. After 2:1 propensity score matching, 397 patients in the azvudine group and 199 patients in the Paxlovid group were enrolled. Cox regression analysis revealed the risk of all-cause death (HR: 1.84, 95% CI: 1.059-3.182, P = 0.030) and composite disease progression (HR: 1.70, 95% CI: 1.043-2.757, P = 0.033) were greater in the Pa

SUBMITTER: Jia B 

PROVIDER: S-EPMC11958667 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature